| http://www.w3.org/ns/prov#value | - To the agency???s chagrin, they found glaring problems the FDA and its expert panel managed to miss.Specifically, they found that muraglitazar (Pargluva??) doubles the risk of heart attack and stroke, and likely raise the risk of cancer.The findings were particularly alarming because some of the increased risks appeared within six months of starting on the drug.
|
